Research Article


DOI :10.26650/IstanbulJPharm.2022.957738   IUP :10.26650/IstanbulJPharm.2022.957738    Full Text (PDF)

Effect of metformin and metformin-sulfonylurea on lipid profile of type 2 diabetes mellitus patients: A cross-sectional study

Rani SauriasariFitriani SyawaliaAzizahwati Azizahwati

Background and Aims: In addition to lowering blood glucose levels, metformin also has a positive effect on the lipid profile by affecting gluconeogenesis and lipogenesis in the liver. Conversely, sulfonylurea is reported to possibly worsen the lipid profile and increase the risk of cardiovascular disease. Therefore, we would like to know whether there is a significant difference in the lipid profile of type 2 diabetes mellitus patients taking metformin as monotherapy and metformin-sulfonylurea as a combination since these two medicines are very commonly used in Indonesia. Methods: A cross-sectional study was performed on 88 patients with type 2 diabetes mellitus who were restricted on metformin or metformin-sulfonylurea for equal to or more than 1 year. Subjects on metformin (n=37) and metformin-sulfonylurea (n=51) were asked to fast for at least 8 hours before blood sampling. We measured the lipid parameters from subjects’ blood samples using a standardized enzymatic method. Results: All basic characteristics of the study subjects in these two groups were matched. We found that total cholesterol, LDL-cholesterol, and triglyceride were lower and HDL-cholesterol was higher in the metformin group than the metforminsulfonylurea group but not statistically significant (p>0.05). Multivariate analysis showed no significant differences for both therapies in any parameters before and after being adjusted by confounders. Only the increase in BMI contributed significantly to the increase in triglyceride. Conclusion: This study presents no statistical differences in lipid profile after ≥1 year consumption of metformin and metformin-sulfonylurea combination.


PDF View

References

  • Adler, A., Shaw, E., Stokes, T., & Ruiz, F. (2009). Newer agents for blood glucose control in type 2 diabetes: summary of NICE guid-ance. BMJ, 338, b1668-b1668. https://doi.org/10.1136/bmj.b1668 google scholar
  • Athyros, V. G., Doumas, M., Imprialos, K. P., Stavropoulos, K., Geor-gianou, E., Katsimardou, A., & Karagiannis, A. (2018). Diabetes and lipid metabolism. Hormones (Athens, Greece), 17(1), 61-67. https:// doi.org/10.1007/s42000-018-0014-8 google scholar
  • Bangert, S. (2008). Hyperlipidaemia: Diagnosis and Management (3rd edn.). Annals of Clinical Biochemistry, 45(6), 619-619. https:// doi.org/10.1258/acb.2008.200814 google scholar
  • Berkowitz, S. A., Krumme, A. A., Avorn, J., Brennan, T., Matlin, O. S., Spettell, C. M., Pezalla, E. J., Brill, G., Shrank, W. H., & Choudhry, N. ,. (2014). Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. JAMA internal medicine, 174(12), 1955-1962. https://doi. org/10.1001/jamainternmed.2014.5294 google scholar
  • Brunton, L., Lazo J, Buxton I, Blumenthal D, Akil H, Amrein P. (2005). Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill google scholar
  • Busti, A. J. (2015). The Mechanism for Metformin’s (Glucophage) Im-provement in the Lipid Profile Beyond its Glucose Lowering Effects in Diabetes Mellitus. Ebmconsult.com. Retrieved 8 March 2018, from https://www.ebmconsult.com/articles/metformin-glucophage-diabetes-lipid-cholesterol-lowering. google scholar
  • Chapman, M. J., Ginsberg, H. N., Amarenco, P,, Andreotti, F., Boren, J., et al European Atherosclerosis Society Consensus Panel. (2011). Triglyceride-rich lipoproteins and high-density lipoprotein cho-lesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal, 32(11), 1345-1361. https://doi.org/10.1093/eurheartj/ehr112 google scholar
  • Chen, Y. H., Du, L., Geng, X. Y., Peng, Y. L., Shen, J. N., Zhang, Y. G., Liu, G. J., & Sun, X. (2015). Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled tri-als. Journal of Evidence-Based Medicine, 8(3), 134-148. https://doi. org/10.1111/jebm.12157 google scholar
  • Davies, M., D’Alessio, D., Fradkin, J., Kernan, W., Mathieu, C., Min-grone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018). Management of hyperglycaemia in type 2 diabetes, 2018. A con-sensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Dia-betologia, 61(12), 2461-2498. https://doi.org/10.1007/s00125-018-4729-5 google scholar
  • Dimitriadis, G., Mitrou, P., Lambadiari, V., Maratou, E., & Raptis, S. A. (2011). Insulin effects in muscle and adipose tissue. Diabetes Research and Clinical Practice, 93 Suppl 1, S52-S59. https://doi. org/10.1016/S0168-8227(11)70014-6 google scholar
  • Florkowski C. (2013). HbA1c as a Diagnostic Test for Diabetes Mellitus - Reviewing the Evidence. The Clinical Biochemist. Re-views, 34(2), 75-83. google scholar
  • Hussain, A., Ali, I., Ijaz, M., & Rahim, A. (2017). Correlation between hemoglobin A1c and serum lipid profile in Afghani patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipid-emia. Therapeutic Advances in Endocrinology and Metabolism, 8(4), 51-57. https://doi.org/10.1177/2042018817692296 google scholar
  • Indonesian Endocrinologist Association (PERKENI). (2015). The consensus in management and prevention of type 2 diabetes mellitus for 2015 Jakarta: Perkeni. https://pbperkeni.or.id/undu-han google scholar
  • Jaiswal, M., Schinske, A., & Pop-Busui, R. (2014). Lipids and lipid management in diabetes. Best Practice & Research Clinical Endo-crinology & Metabolism, 28(3), 325-338. https://doi.org/10.1016/j. beem.2013.12.001 google scholar
  • Kashi, Z., Mahrooz, A., Kianmehr, A., & Alizadeh, A. (2016). The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Met-formin. PloS one, 11(3), e0151543. https://doi.org/10.1371/journal. pone.0151543 google scholar
  • Laisupasin, P., Thompat, W., Sukarayodhin, S., Sornprom, A., & Sudjaroen, Y. (2013). Comparison of Serum Lipid Profiles be-tween Normal Controls and Breast Cancer Patients. Journal of Laboratory Physicians, 5(1), 38-41. https://doi.org/10.4103/0974-2727.115934 google scholar
  • Li, Y., Hu, Y., Ley, S. H., Rajpathak, S., & Hu, F. B. (2014). Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Dia-betes care, 37(11), 3106-3113. https://doi.org/10.2337/dc14-1306 Madsen, A., Bozickovic, O., Bjune, J.I., Mellgren. G., Sagen, J. V. (2015). Metformin inhibits hepatocellular glucose, lipid and cholesterol biosynthetic pathways by transcriptionally suppress-ing steroid receptor coactivator 2 (SRC-2). Sci Rep. doi: 10.1038/ srep16430. PMID: 26548416; PMCID: PMC4637908. google scholar
  • Middleton, T. L., Wong, J., Molyneaux, L., Brooks, B. A., Yue, D. K., Twigg, S. M., & Wu, T. (2017). Cardiac Effects of Sulfonylurea-Re-lated Hypoglycemia. Diabetes Care, 40(5), 663-670. https://doi. org/10.2337/dc16-1972 google scholar
  • Ministry of Health. (2013). Basic Health Research 2013. Jakarta: Ministry of Health Republic of Indonesia. https://www.litbang. kemkes.go.id/laporan-riset-kesehatan-dasar-riskesdas/ google scholar
  • Natali, A., & Ferrannini, E. (2006). Effects of metformin and thia-zolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a system-atic review. Diabetologia, 49(3), 434-441. https://doi.org/10.1007/ s00125-006-0141-7 google scholar
  • Nuttall, F. Q. (2015). Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutrition today, 50 (3), 117-128. https://doi. org/10.1097/NT.0000000000000092 google scholar
  • Rao, A. D., Kuhadiya, N., Reynolds, K., & Fonseca, V. A. (2008). Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care, 31(8), 16721678. https://doi.org/10.2337/dc08-0167 google scholar
  • Sauriasari, R., Andriany, R., Sekar, A., & Azizahwati, A. (2017). Com-parison of Antioxidative Effect of Metformin and Combination of Metformin-Sulfonylurea in Type 2 Diabetes Mellitus Patients. Journal of Young Pharmacists, 9(1), 39-42. https://doi.org/10.5530/ jyp.2017.1s.10 google scholar
  • Sauriasari, R., Aristia H., Azizahwati (2020). Urine albumin-to-cre-atinine ratio and estimated glomerular filtration rate in matched groups of type 2 diabetes mellitus patients receiving metformin and metformin-sulfonylurea. International Journal of Applied Phar-maceutics. 12(Special Issue I), 257-259. DOI: 10.22159/ijap.2020. v12s1.FF056 google scholar
  • Schofield, J. D., Liu, Y., Rao-Balakrishna, P., Malik, R. A., & Soran, H. (2016). Diabetes Dyslipidemia. Diabetes therapy: research, treat-ment and education of diabetes and related disorders, 7(2), 203219. https://doi.org/10.1007/s13300-016-0167-x google scholar
  • Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S. H., Bardeesy, N., De-pinho, R. A., Montminy, M., & Cantley, L. C. (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (New York, N.Y.), 310(5754), 1642-1646. https:// doi.org/10.1126/science.1120781 google scholar
  • Sola, D., Rossi, L., Schianca, G., Maffioli, P., Bigliocca, M., & Mella, R. et al. (2015). State of the art paper Sulfonylureas and their use in clinical practice. Archives Of Medical Science, 4, 840-848. https:// doi.org/10.5114/aoms.2015.53304 google scholar
  • Tsimihodimos, V., Gonzalez-Villalpando, C., Meigs, J., & Ferrannini, E. (2018). Hypertension and Diabetes Mellitus. Hypertension, 71(3), 422-428. https://doi.org/10.1161/hypertensionaha.117.10546 google scholar
  • WHO. Diabetes. Who.int. (2021). Retrieved 10 November 2021, from http://www.who.int/news-room/fact-sheets/detail/diabe-tes. google scholar
  • Zhang, F., Xiang, H., Fan, Y., Ganchuluun, T. A., Kong, W., Ouyang, Q., Sun, J., Cao, B., Jiang, H., & Nie, S. (2013). The effects of sulfo-nylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized con-trolled trials. Endocrine, 44(3), 648-658. https://doi.org/10.1007/ s12020-013-9970-6 google scholar
  • Zhang, X., Song, Y., Feng, M., Zhou, X., Lu, Y., Gao, L., Yu, C., Jiang, X., & Zhao, J. (2015). Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation via AMP-activated protein kinase in the liver. Journal of Lipid Research, 56(5), 963-971. https://doi. org/10.1194/jlr.M047654 google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Sauriasari, R., Syawalia, F., & Azizahwati, A. (2022). Effect of metformin and metformin-sulfonylurea on lipid profile of type 2 diabetes mellitus patients: A cross-sectional study. İstanbul Journal of Pharmacy, 52(2), 114-120. https://doi.org/10.26650/IstanbulJPharm.2022.957738


AMA

Sauriasari R, Syawalia F, Azizahwati A. Effect of metformin and metformin-sulfonylurea on lipid profile of type 2 diabetes mellitus patients: A cross-sectional study. İstanbul Journal of Pharmacy. 2022;52(2):114-120. https://doi.org/10.26650/IstanbulJPharm.2022.957738


ABNT

Sauriasari, R.; Syawalia, F.; Azizahwati, A. Effect of metformin and metformin-sulfonylurea on lipid profile of type 2 diabetes mellitus patients: A cross-sectional study. İstanbul Journal of Pharmacy, [Publisher Location], v. 52, n. 2, p. 114-120, 2022.


Chicago: Author-Date Style

Sauriasari, Rani, and Fitriani Syawalia and Azizahwati Azizahwati. 2022. “Effect of metformin and metformin-sulfonylurea on lipid profile of type 2 diabetes mellitus patients: A cross-sectional study.” İstanbul Journal of Pharmacy 52, no. 2: 114-120. https://doi.org/10.26650/IstanbulJPharm.2022.957738


Chicago: Humanities Style

Sauriasari, Rani, and Fitriani Syawalia and Azizahwati Azizahwati. Effect of metformin and metformin-sulfonylurea on lipid profile of type 2 diabetes mellitus patients: A cross-sectional study.” İstanbul Journal of Pharmacy 52, no. 2 (Oct. 2022): 114-120. https://doi.org/10.26650/IstanbulJPharm.2022.957738


Harvard: Australian Style

Sauriasari, R & Syawalia, F & Azizahwati, A 2022, 'Effect of metformin and metformin-sulfonylurea on lipid profile of type 2 diabetes mellitus patients: A cross-sectional study', İstanbul Journal of Pharmacy, vol. 52, no. 2, pp. 114-120, viewed 3 Oct. 2022, https://doi.org/10.26650/IstanbulJPharm.2022.957738


Harvard: Author-Date Style

Sauriasari, R. and Syawalia, F. and Azizahwati, A. (2022) ‘Effect of metformin and metformin-sulfonylurea on lipid profile of type 2 diabetes mellitus patients: A cross-sectional study’, İstanbul Journal of Pharmacy, 52(2), pp. 114-120. https://doi.org/10.26650/IstanbulJPharm.2022.957738 (3 Oct. 2022).


MLA

Sauriasari, Rani, and Fitriani Syawalia and Azizahwati Azizahwati. Effect of metformin and metformin-sulfonylurea on lipid profile of type 2 diabetes mellitus patients: A cross-sectional study.” İstanbul Journal of Pharmacy, vol. 52, no. 2, 2022, pp. 114-120. [Database Container], https://doi.org/10.26650/IstanbulJPharm.2022.957738


Vancouver

Sauriasari R, Syawalia F, Azizahwati A. Effect of metformin and metformin-sulfonylurea on lipid profile of type 2 diabetes mellitus patients: A cross-sectional study. İstanbul Journal of Pharmacy [Internet]. 3 Oct. 2022 [cited 3 Oct. 2022];52(2):114-120. Available from: https://doi.org/10.26650/IstanbulJPharm.2022.957738 doi: 10.26650/IstanbulJPharm.2022.957738


ISNAD

Sauriasari, Rani - Syawalia, Fitriani - Azizahwati, Azizahwati. Effect of metformin and metformin-sulfonylurea on lipid profile of type 2 diabetes mellitus patients: A cross-sectional study”. İstanbul Journal of Pharmacy 52/2 (Oct. 2022): 114-120. https://doi.org/10.26650/IstanbulJPharm.2022.957738



TIMELINE


Submitted19.08.2021
Accepted27.05.2022
Published Online29.08.2022

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.